Top

Neurological Sciences

Published in:

Open Access 01-09-2020 | Cluster Headache | Letter to the Editor

Anti-CGRP in cluster headache therapy: a response

Authors: Richard Wenzel, Jennifer Bardos, Sheena Aurora

Published in: Neurological Sciences | Issue 9/2020

Excerpt

Dear Editor in Chief, …

Dodick D, Goadsby PJ, Lucas C, et al (2019) Phase 3 placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. American Headache Society - 61st Annual Scientific Meeting;59(S1):1–208

Goadsby PJ, Dodick DW, Leone M et al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381:132–141CrossRef

Title: Anti-CGRP in cluster headache therapy: a response
Authors: Richard Wenzel
Jennifer Bardos
Sheena Aurora
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keywords: Cluster Headache
Galcanezumab
Fremanezumab
Published in: Neurological Sciences / Issue 9/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04335-3

At a glance: The STEP trials

Springer Medicine

Anti-CGRP in cluster headache therapy: a response

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2020

Frequency and outcome of olfactory impairment and sinonasal involvement in hospitalized patients with COVID-19

A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients

A case of adult-onset neuronal intranuclear inclusion disease without abnormal high-intensity signal in the corticomedullary junction in diffusion-weighted imaging

Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis

Clinical features of fallers among inpatient subacute stroke: an observational cohort study

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients